Meeting report: initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
The development of vaccines against herpes simplex virus (HSV) is an important global goal for sexual and reproductive health. A key priority to advance development of HSV vaccines is the definition of preferred product characteristics (PPCs), which provide strategic guidance on World Health Organization (WHO) preferences for new vaccines, specifically from a low- and middle-income country (LMIC) perspective. To start the PPC process for HSV vaccines, the WHO convened a global stakeholder consultation in March 2017, to define the priority public health needs that should be addressed by HSV vaccines and discuss the key considerations for HSV vaccine PPCs, particularly for LMICs. Meeting participants outlined an initial set of overarching public health goals for HSV vaccines in LMICs, which are: to reduce the acquisition of HIV associated with HSV-2 infection in high HIV-prevalence populations and to reduce the burden of HSV-associated disease, including mortality and morbidity due to neonatal herpes and impacts on sexual and reproductive health. Participants also considered the role of prophylactic versus therapeutic vaccines, whether both HSV-2 and HSV-1 should be targeted, important target populations, and infection and disease endpoints for clinical trials. This article summarizes the main discussions from the consultation.
Date Issued
2019-11-28
Date Acceptance
2017-12-01
Citation
Vaccine, 2019, 37 (50), pp.7408-7418
ISSN
0264-410X
Publisher
Elsevier
Start Page
7408
End Page
7418
Journal / Book Title
Vaccine
Volume
37
Issue
50
Copyright Statement
© 2017 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000501402100016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
Medicine, Research & Experimental
Research & Experimental Medicine
Herpes simplex virus
Sexually transmitted infections
Vaccines
HSV vaccines
Preferred product characteristics
Genital herpes
HUMAN-IMMUNODEFICIENCY-VIRUS
PLASMID DNA VACCINE
GENITAL HERPES
THERAPEUTIC VACCINE
HIV-1 TRANSMISSION
TYPE-2 INFECTION
T-CELLS
WOMEN
IMMUNOGENICITY
ACQUISITION
Publication Status
Published
Date Publish Online
2017-12-08